Stifel analyst Daniel Arias upgraded Agilent Technologies to Buy from Hold with a price target of $163, up from $145. The firm says responses from its biopharma survey suggest some good second half of 2024 acceleration in instrument demand. When coupled with a few “less-than-bullish” data points on consumables side, Agilent’s relative attractiveness has increased, the analyst tells investors in a research note. Stifel says Agilent shares, the cheapest of the instrument names, has become increasingly compelling as a 12-month idea.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Agilent announces participation at AACR annual meeting
- China stimulus positive for GE HealthCare, tool companies, says Evercore ISI
- Early notable gainers among liquid option names on February 28th
- Agilent price target raised to $141 from $138 at BofA
- Agilent price target raised to $163 from $156 at TD Cowen
